To explore the possibility of using gene transfer to provide iduronate-2-sulfatase (IDS; EC 3. 
Hunter syndrome, or mucopolysaccharidosis (MPS) type II, is an X chromosome-linked recessive inborn error of metabolism resulting from the deficiency of lysosomal iduronate-2-sulfatase (IDS; EC 3.1.6.13) enzyme activity and the consequent systemic accumulation ofglycosaminoglycan (GAG) substrates, heparan sulfate and dermatan sulfate (for review, see refs. [1] [2] [3] . The disorder is clinically manifest as coarse facial features, dysostosis multiplex, joint contractures, hepatosplenomegaly, and obstructive airway disease. In the severe form, children experience progressive mental retardation and die before 15 (4) . More recently, similar results have been obtained by coculture with normal lymphocytes or macrophages (5) (6) (7) (8) . Such studies provided important insights into the posttranslational processing, trafficking, and reuptake of lysosomal enzymes. Early attempts to replace IDS enzyme activity in patients with Hunter syndrome by infusion of normal plasma (9) or leukocytes (10) yielded equivocal results. However, clinical trials of allogeneic bone marrow transplantation have provided evidence of metabolic correction in some tissues (11) . Unfortunately, application of bone marrow transplantation is limited by lack of histocompatible donors, a significant mortality rate of
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As a means of circumventing problems associated with marrow transplantation, gene transfer targeted at autologous marrow cells has been proposed as an alternative treatment for lysosomal storage diseases (12) (13) (14) (15) (16) . Sequencing was performed using Sequenase (United States Biochemical) and dideoxynucleotide chain-termination (17) . PCR was conducted using Taq DNA polymerase (Cetus) in an automated thermal cycler (Perkin-Elmer/Cetus).
Construction of pL2SN. For construction of the retrovirus pL2SN ( Fig. 1) , the 3' portion of the IDS coding sequence was generated by reverse transcription linked to PCR using total RNA extracted from human leukocytes as template (20) . A BamHI site was introduced at base 1669 (enumerated relative to the translational start site) by reamplification ofthe 3' product using an antisense oligonucleotide primer IDS2 (5'-CATTTGGGATCCATGGTTGG-3') and a sense primer IDS3 (5'-ATGAAAACGTCAGCCAGTCC-3'). PCR conditions were 60 s at 94°C, 60 s at 55°C, and 60 s at 72°C for 30 cycles. The (18) were grown in DMEM with 10% heat-inactivated newborn calf serum (HyClone). All media were supplemented with 2 mM glutamine (Sigma), penicillin (50 units/ ml), streptomycin sulfate (50 mg/ml), and Fungizone (125 mg/ml) (GIBCO). Penicillin, streptomycin sulfate, and Fungizone were omitted for experiments employing 35SO4 labeling of GAG (below). Cultures were incubated in a humidified atmosphere of 5% C02/95% air at 37°C.
Retrovirus constructs were packaged by transfection into GP+E86 cells using DNA-calcium phosphate coprecipitation (24, 25). Transiently generated virus was then used to transduce PA317 cells (21) isolating G418-resistant (0.4 mg of active base per ml, GIBCO/BRL) clones and screening for those producing the highest titer of G418-resistant virus using NIH 3T3 cells as targets (26) .
Transduction and Selection. LCLs were transduced by incubating overnight for 3 consecutive days with retroviral supernatant (2:1 colony-forming units/cell ratio) and Polybrene (8 ,g/ml, Sigma). LCLs were expanded for 2 weeks. To select for transductants, LCL cultures were then grown in medium containing G418 (0.4 mg/ml) for 2 additional weeks and, thereafter, maintained in medium containing G418 (1.0 mg/ml).
Southern Blot Analysis. To verify transduction and integrity of proviral integrants by Southern blot analysis, genomic DNA was isolated, digested with Kpn I, and electrophoresed in 0.8% agarose gel prior to transfer to Zetabind membrane (Cuno). The membrane was baked at 80°C for 2 hr and then washed twice in 0.1x standard saline citrate (SSC)/0.1% SDS at 60°C for 1 hr. Prehybridization was in 5.4x standard saline/phosphate/EDTA (16)/1500 units (U) of heparin/llx Denhardt's solution/0.8% SDS/salmon sperm DNA (200 Mg/ml)/50% (vol/vol) formamide for 6 hr at 42°C. To probe for IDS sequences, the EcoRI fragment of pc2S15 was purified and 32P-radiolabeled by random priming (27) . After overnight hybridization in prehybridization solution and IDS probe, the membrane was washed three times in 0.1 x SSC/ 0.1% SDS for 15 min at ambient temperature and three times in 0.lx SSC/0.1% SDS for 30 min at 60°C.
Determination of Enzyme Activities. Peripheral blood leukocytes and LCLs were disrupted by one freeze-thaw cycle and then sonicated (three 15-s bursts at level 7, Branson Sonifier 450) in 1% Triton X-100. Cell sonicates, or culture media, were then desalted into distilled water by centrifugal column chromatography (Bio-Gel P-10, fine mesh, Bio-Rad). IDS enzyme activity was measured in extracts using the tritiated disaccharide substrate L-O-(a-iduronate-2-sul- duction and proviral integration in PA317 and LCLMpS was obtained by Southern blot analysis (Fig. 2) . Probing Kpn I-digested genomic DNA from these cell lines with an IDSspecific fragment from pc2S15 (19) 35SO4-GAG Accumulation in LCLs. To evaluate the ability of L2SN transduction to correct the metabolic defect, 3SO4-GAG levels were studied in LCL cultures (Fig. 3) L2SN demonstrated even lower 35S04-GAG accumulation (58%), a reduction that was significantly different (P < 0.01) from fibroblasts cocultured with LCLMpS-LXSN. This greater metabolic cross-correction by LCLMpS-L2SN was presumably the result of increased retroviral IDS enzyme expression, release, and uptake by fibroblasts.
DISCUSSION
We constructed a recombinant retroviral vector L2SN to mediate insertion and expression of human IDS cDNA in lymphohematopoietic target cell populations. As a model system for studying gene transfer, expression of enzyme and metabolic correction, LCL established from patients with Hunter syndrome were targeted for L2SN transduction. Cells transduced with L2SN were selected in medium containing G418 and were found to contain a remarkably high level of IDS enzyme activity, levels 10-to 70-fold greater than either normal LCLs or normal human leukocytes. Recombinant IDS enzyme appears to undergo essentially normal posttranslational modification and trafficking to lysosomes as indicated by a substantial reversal of GAG substrate accumulation, not only in L2SN-transduced LCLMpS but also in cocultivated Hunter fibroblasts. We propose that this high level of IDS expression mediated by the strong heterologous promoter is characteristic of lysosomal enzymes in general. Several recent studies demonstrating expression of cDNA for other human lysosomal enzymes have observed similarly high levels of expression from heterologous promoters. Arylsulfatase A was expressed in fibroblasts at levels 10-fold greater than that ofnormal cells (31) , acid sphingomyelinase was expressed 16-fold above normal (32) , arylsulfatase B was overexpressed by 36-fold (33) , a-L-iduronidase was expressed at 50-to 250-fold (12) , and a-L-fucosidase was expressed 30-to 400-fold over normal levels (34) . Our results with IDS are thus consistent with the high levels of lysosomal enzyme expression after gene transfer when the coding sequence is transcriptionally regulated by strong heterologous promoters. Conversely, this implies a relatively low level of basal expression by endogenous lysosomal enzyme genes in the native state.
As early as 1963, Bemlohr (35) suggested that expression of lysosomal enzymes at normal levels is well in excess of the metabolic demand and that altered kinetics of an aberrant enzyme would lead to a higher steady-state concentration of substrate or even progressive accumulation in affected individuals. More recently, Sandhoff and colleagues expanded upon this kinetic model proposing a relationship between the phenotype (e.g., age of onset and clinical severity) and small quantitative differences in residual enzyme activity (36); they subsequently provided experimental data correlating the residual activity of lysosomal enzymes and the turnover of substrate in cell culture (37 (38) (39) (40) (41) and in animals (42, 43) has fueled speculation that gene transfer into autologous lymphohematopoietic cells may provide an alternate therapy.
Recent in vitro studies of retrovirus-mediated gene expression have shown that several recombinant lysosomal enzymes become localized to the lysosome of transduced cells (12, 31) and normalize substrate degradation (12, 15, 31) , suggesting that posttranslational modification and trafficking of recombinant enzyme is normal. Other studies of purified recombinant lysosomal enzymes have suggested that these enzymes are properly glycosylated for uptake (12, 44, 45) . However, extreme overexpression may result in intracellular aggregation of recombinant enzyme (45) 
